Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
KEPPRA XR is an extended-release oral tablet formulation of levetiracetam, a small-molecule antiepileptic agent used to treat seizure disorders. The drug is indicated for adjunctive therapy in epilepsy and works through mechanisms that reduce neuronal hyperexcitability, though its precise pharmacological mechanism remains incompletely understood. It is widely used across multiple seizure types in both adult and pediatric populations.
Product is in late-stage commercial maturity with patent expiration in 2.3 years, signaling transition from growth-oriented to defense and transition planning for brand teams.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy
An Investigation of Levetiracetam in Alzheimer's Disease
A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age
Effects of Augmented Renal Clearance on Pharmacokinetic and Pharmacodynamic Properties of Levetiracetam in Subarachnoid Hemorrhage
A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers
Worked on KEPPRA XR at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
Working on KEPPRA XR positions professionals for expertise in mature-market brand defense, payer negotiation, and transition planning as the product approaches loss of exclusivity. Career growth on this product requires strategic mindset around lifecycle extension, generic competition management, and organizational restructuring typical of LOE transitions.